Who is fooling us? [2]

Lancet

Volumn 360, Issue 9326, 2002, Pages 89-

  Mourad, Jean Jacques ^a,b,c   Safar, Michel E ^a,b,c   O'Rourke, Michael F ^a,b,c  

^a Hospital St Michel   (France)

^b HÔPITAL BROUSSAIS   (France)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLACEBO; RAMIPRIL; STATIN;

BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; LETTER; MORBIDITY; MORTALITY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR; STROKE; SYSTOLIC BLOOD PRESSURE;

EID: 0037031063     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(02)09348-0     Document Type: Letter

References (5)

1. Effects of an angiotensin converting-enzyme inhibitor, ramipril, on death from cardiovascular causes, myocardial infarction and stroke in high-risk patients
2. Blood-pressure reduction and cardiovascular risk in HOPE study
3. Comparative effects of ramipril on ambulatory and office blood pressures: A HOPE substudy
4. Randomised trial of a perindopril-based blood pressure lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack
5. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy